Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients

Journal of Investigative Medicine

Volumn 59, Issue 5, 2011, Pages 823-828

  Coppolino, Giuseppe ^a,b,c   Bolignano, Davide ^b   De Paola, Luciano ^a   Giulino, Crispino ^a   Mannella, Ada ^a   Riccio, Mara ^b   Mascaro, Maria Antonietta ^c   Lombardi, Gianmarco ^a   Fuiano, Giorgio ^c   Lombardi, Luigi ^a   Buemi, Michele ^b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bone marrow; Endothelial progenitor cells; Parathyroid hormone; Uremia

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CD31 ANTIGEN; CD45 ANTIGEN; CINACALCET; PARACALCITRIOL; PARATHYROID HORMONE; STEM CELL FACTOR; UNCLASSIFIED DRUG; CD34 ANTIGEN;

ARTICLE; BONE MARROW CELL; CD34 SELECTION; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HEMATOPOIETIC CELL; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; STEM CELL MOBILIZATION; UREMIA; ADULT; COHORT ANALYSIS; HEMATOPOIETIC STEM CELL; HEMODIALYSIS; MIDDLE AGED; PRACTICE GUIDELINE; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY AND SPECIFICITY;

EID: 85047688735     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318214edf8     Document Type: Article

References (31)

1. Napoli C, William-Ignarro S, Byrns R, et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med. 2008;5(9):571-579.
2. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343-353. (Pubitemid 39100452)
3. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1(6):635-645. (Pubitemid 350215330)
4. Ballen KK, Shpall EJ, Avigan D, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13(7):838-843. (Pubitemid 46902439)
5. Brunner S, Zaruba MM, Huber B, et al. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol. 2008;36(9):1157-1166.
6. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO (4), Ca x PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-2138. (Pubitemid 32880350)
7. de Francisco AL. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs. Expert Opin Pharmacother. 2006;7(16):2215-2224.
8. Mazzaferro S, Pasquali M, Farcomeni A, et al. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant. 2008;23(7):2319-2323. (Pubitemid 351957582)
9. Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24(7):1246-1252. (Pubitemid 38880016)
10. Leuner S, Arland M, Kahl C, et al. Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Bone Marrow Transplant. 1998;22(7):699-706. (Pubitemid 28486371)
11. + cell count is associated with poor prognosis in chronic hemodialysis patients. Kidney Int. 2008;74(12):1603-1609.
12. Garrett RW, Emerson SG. The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology. Mol Cell Endocrinol. 2008;288(1-2):6-10.
13. Jansen J, Hanks S, Thompson JM, et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med. 2005;9(1):37-50.
14. Allegra A, Coppolino G, Bolignano D, et al. Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol. 2009;22(4):463-475.
15. Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342(9):626-633. (Pubitemid 30118415)
16. Bahlmann FH, De Groot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64(5):1648-1652. (Pubitemid 37323692)
17. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1-E7.
18. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004;109(2):220-226. (Pubitemid 38114143)
19. Coppolino G, Buemi A, Bolignano D, et al. Perioperative iloprost and endothelial progenitor cells in uremic patients with severe limb ischemia undergoing peripheral revascularization. J Surg Res. 2009;157(1): e129-e135.
20. Coppolino G, Bolignano D, Campo S, et al. Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. Hypertens Res. 2008;31(4):717-724. (Pubitemid 351772863)
21. Sturiale A, Coppolino G, Loddo S, et al. Effects of haemodialysis on circulating endothelial progenitor cell count. Blood Purif. 2007;25(3):242-251. (Pubitemid 47074637)
22. Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25(2):238-243. (Pubitemid 46227124)
23. Blair HC, Julian BA, Cao X, et al. Parathyroid hormone-regulated production of stem cell factor in human osteoblasts and osteoblast-like cells. Biochem Biophys Res Commun. 1999;255(3):778-784. (Pubitemid 29294875)
24. Zaruba MM, Huber BC, Brunner S, et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res. 2008;77(4):722-731. (Pubitemid 351301860)
25. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol. 2002;283(3):F367-F376.
26. Wood C, Gonzalez EA, Martin KJ. Challenges in the therapy of secondary hyperparathyroidism. Ther Apher Dial. 2005;9(1):4-8. (Pubitemid 40393316)
27. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 suppl 3):S1-S201.
28. Buemi M, Corica F, Marino D, et al. Cardiovascular remodeling, apoptosis, and drugs. Am J Hypertens. 2000;13 (4 pt 1):450-454.
29. Buemi M, Allegra A, Corica F, et al. Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Am J Hypertens. 1999;12 (1 pt 1):73-75. (Pubitemid 29118233)
30. Herbrig K, Pistrosch F, Oelschlaegel U, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis. 2004;44(5):840-849. (Pubitemid 39445916)
31. Brunner S, Theiss HD, Murr A, et al. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab. 2007;293(6):E1670-E1675. (Pubitemid 350255118)